Exploring Semaglutide: Therapy for Obesity and Heart Failure

About this episode

This episode explores a study on the effects of semaglutide in obese patients with heart failure and type 2 diabetes.

Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes. For full paper, click here Visit HormoneInsight

People in this episode

Host: FWA

Topics covered

• semaglutide
• obesity
• heart failure
• type 2 diabetes
• medical research

Keywords

• semaglutide
• obesity
• heart failure
• type 2 diabetes
• New England Journal of Medicine

Mentioned in this episode

Organizations: New England Journal of Medicine

Products: semaglutide

Places: 2024

More episodes of Hormone Insight

• The Week in Endocrinology Oral Ozempic & Emerging Therapies · May 12, 2026 · 5 min
• Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial · May 5, 2026 · 16 min
• HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026 · April 24, 2026 · 14 min
• The Week in Diabetes and Endocrinology April 17, 2026 · April 22, 2026 · 18 min
• Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026) · April 9, 2026 · 17 min
• The Week in Diabetes and Endocrinology -- April 3, 2026 · April 5, 2026 · 24 min